A cikin 'yan shekarun nan, tallace-tallace naapixabansun girma cikin sauri, kuma kasuwar duniya ta riga ta zarcerivaroxaban.Domin Eliquis (apixaban) yana da fa'ida akan warfarin wajen hana bugun jini da zubar jini, da Xarelto (Rivaroxaban) kawai ya nuna rashin ƙasƙanci.Bugu da kari,Apixabanbaya buƙatar gyare-gyaren sashi mai rikitarwa, kuma magani ya fi dacewa.Wannan jerin rashin amfani ya haifarrivaroxabandon rasa ƙasa a kasuwar Amurka.

Duk da haka, a babban yankin kasar Sin,rivaroxabanyana da ƙarin alamu a duniya da kuma a cikin babban yankin kasar Sin.The lamban kira karewa lokacin narivaroxabanya fi kusa, kuma samun maganin zai haifar da yawan jama'arivaroxabanGeneric kwayoyi zuwa muhimmanci fiye da naApixaban.

Bisa kididdigar da Xianda ya bayar, an ce, cinikin rivaroxaban a kasuwannin cikin gida a shekarar 2018 ya kai yuan biliyan 2.8.A cewar sanarwar Huahai Pharmaceutical, tallace-tallacen kasuwannin asibiti na cikin gida narivaroxabana shekarar 2018 ya kai Yuan biliyan 1.527.

Tabbas, jeri na magunguna na yau da kullun zai haifar da faduwa mai kaifi a cikin farashin rana gudarivaroxaban.Yin la'akari da cewa a cikin duk NOACs, haƙƙin mallaka narivaroxabanmahadi suna ƙarewa a cikin 2020 a farkon (alamomin mallaka donapixabanda dabigatran etexilate sun fi tsayi Na dogon lokaci), babu shakka zai zama da amfani ga cikakken haɓakawa.rivaroxabanmagunguna don maye gurbin warfarin.Idan farashin yau da kullun narivaroxabanAn harba magunguna na yau da kullun daga yuan 27.6 zuwa yuan 2.76, kuma za a karfafa wannan yanayin.

Yawan aikace-aikacen da kawai ke la'akari da marasa lafiya tare da fibrillation (AF) ma ban mamaki ne.Adadin marasa lafiya da ke fama da fibrillation a kasar Sin kusan miliyan 10 ne, wanda kusan miliyan 2 daga cikin su ne na valvular atrial fibrillation da kuma game da miliyan 7 ga wadanda ba valvular atrial fibrillation.Binciken da aka yi a shekarar 2016 an gano cewa, yawan wayar da kan jama'a game da cutar fibrillation a yankin kasar Sin ya kai kashi 40 cikin 100, kuma yawan rigakafin cutar jini ya kai kashi 30%.Rivaroxaban ya dace don amfani, baya buƙatar saka idanu na yau da kullun na alamun coagulation, kuma adadin rigakafin cutar zai kuma inganta sosai.An annabta cewa kwayoyin magani narivaroxabanzai kasance a kasar Sin.Girman kasuwa da aka yi amfani da shi a cikin marasa lafiya tare da fibrillation na valvular ba tare da fibrillation ba: marasa lafiya miliyan 7 * 30% adadin maganin hana daukar ciki * 50% adadin shiga * 2.76 yuan / rana * 365 kwanaki = yuan miliyan 157.

Bugu da ƙari, an yi la'akari da tsammanin kasuwa don rigakafi da kula da marasa lafiya na VTE.Bisa kididdigar da cibiyar rigakafin VTE da ke Amurka ta fitar, adadin masu cutar VTE a Amurka ya kai 900,000 a kowace shekara, kuma adadin mutanen da ke mutuwa ta hanyar VTE ya kai 60,000 zuwa 100,000, kuma akwai Rikice-rikice na dogon lokaci (irin su DVT) marasa lafiya sun kai 50%, kuma adadin sake dawowa cikin shekaru 10 ya kai 33%.

Saboda yawan tsufa na kasar Sin, kuma yawan jama'a ya ninka na Amurka sau 4 (mutane biliyan 1.395).Ana iya hasashen cewa akwai marasa lafiya VTE miliyan 3.6 a kasar Sin a kowace shekara.Tsammanin cewa adadin jiyya na watanni 3 narivaroxabanshine 80%, girman kasuwa shine: 3.6 miliyan marasa lafiya * 80% adadin magani * 2.76 yuan / rana * kwanaki 92 = yuan miliyan 731.

Don haka, idan aka yi la'akari da alamun biyu na AF da VTE kawai, girman kasuwar cikin gida na magungunan rivaroxaban ya kusan kusan yuan biliyan 2.Ya isa ya sa kamfanonin harhada magunguna na cikin gida su yi gaggawar neman jeri.

Mu,Kamfanin Magunguna na Changzhou, kuma samarapxiabankumarivaroxban, kuma duka biyu suna da DMF.RivaroxabanAna aiwatar da aikace-aikacen CEP da WC.